تأثير عقار السبروفلوكساسين على مستوى خميرة الفوسفاتيز القاعية في الفئران السليمة
Article Sidebar
Published:
Jun 28, 1999
Keywords:
mice, ciprofloxacin, alkaline phosphates
Main Article Content
Abstract
This study was designed to investigate the effects of ciprofloxacin on-serum alkaline phosphates level in normal mice , the dosage used is treatment and double dose (5
10 mg / kg ) orally for 5 days . The result showed that ciprofloxacin caused a marked increase in serum alkaline phosphates with the increase of dose, and this may be releated to the damage of cell in liver , kidney and bone
Downloads
Article Details
How to Cite
تأثير عقار السبروفلوكساسين على مستوى خميرة الفوسفاتيز القاعية في الفئران السليمة. (1999). The Iraqi Journal of Veterinary Medicine, 23(1), 79-85. https://doi.org/10.30539/ijvm.v23i1.1195
Section
Articles
How to Cite
تأثير عقار السبروفلوكساسين على مستوى خميرة الفوسفاتيز القاعية في الفئران السليمة. (1999). The Iraqi Journal of Veterinary Medicine, 23(1), 79-85. https://doi.org/10.30539/ijvm.v23i1.1195
References
1-Abadia , A.R. Francisco, L.DE and Guaitani A (1995). Disposition of ciprofloxacin in the isolated perfused rat liver. The American Society for pharmacology and
experimental therapeutics : 23 , 197 - 200.
2-Aramayona J.J; Jaume M; Lorenzo . J Fraile ; Maria A. Grasia; Ana R. Abadia; Miguel A. Bregant (1996). Penetration of enterofloxacin and ciprofloxacin into milk, and pharma cokinetics of the drugs in lactating rabbits and neonatal offspring . AJVR. 57 (4): 547 – 553.
3-Arcier, G.M; Nancy Beker (1989). Safety of intravenous ciprofloxacin . AJM. Nov. 30 ; 87 (suppl 5 A). 92s – 97s)
4-Caekenberge, D.V. Stefanr Pattyn (1984). In vitro activity of ciprofloxacin compared with those new fluorinated piprazinyi supstituted quinoline derevatives.
Antimicrobial agent chemotherapy 25(3) 518-521.
5- Frost, R.W; Lettieri ;. J.T; Krol G; Shambien E.C and Laiseter K.C (1989) . The effect of cirohosis on the steady-state pharmacokinetics of oral ciprofloxacin .
Pharmacol. Ther. 45: 608 – 616.
6-Gudiol F ; Carmen Cabellos ; Roman Pallares; Josefina L; Javier A (1989). Intravenous ciprofloxacin therapy severe infections AJM.
Nov. 30 87 (suppl. 5 A): 2218 -227S.
7- Halkin G. (1988). Adverse effects of the fluoroquinolo - nes . Rview of infectious disease. 10 ( suppl./1 ): 5258 5261.
8- Harper A. Harlod (1971). Review of physiological chemistry (15 th.) edition. Lange . Medical publication . San Francisco. Japan.
9-Neer T.M. (1988). Clinical pharmacological features of fluoroquinolone antimicrobial drugs .JAVMA. 193 (5): 577 -579.
10- Richards D.M; Mouk J.P; Price . A; Field . B; Todd P.A. and ward (1988). Ciprofloxacin : a review of its antibacterial activity pharmacokinetic properties and
therapeutics use . Drugs . 53, 373 – 447.
11- Schacht P; hullman R. (1989) Safety of oral ciprofloxacin . A.JM. 87 (suppl. 5A ): 989 -102s.
12- Schalm D.W; Jain N.C. and Carroll E.J. (1980) Veterinary hematology (4'h.) edition . P(514). Lea Febbiger , Philadelphia
13- Shah, P.M; Rotraud M (1990) · Safety profile of quinolones . Eur. Uro ; 17(suppl / 1): 46 – 51 (13ref).
14- Villenenve, J.P; Davies C and Cote J. (1995) suspected ciprofloxacin induced hepatotxicity. Ann.
Pharmacotherapy , 29: 257 – 259.
15- Wolfson, J.S. and Hooper D.C. (1985) . The fluoro quinolones structure , mechanism of action resistance and spectra of activity invitro. Antimicrob .Agents and Chemother.
28: 581 - 586.
experimental therapeutics : 23 , 197 - 200.
2-Aramayona J.J; Jaume M; Lorenzo . J Fraile ; Maria A. Grasia; Ana R. Abadia; Miguel A. Bregant (1996). Penetration of enterofloxacin and ciprofloxacin into milk, and pharma cokinetics of the drugs in lactating rabbits and neonatal offspring . AJVR. 57 (4): 547 – 553.
3-Arcier, G.M; Nancy Beker (1989). Safety of intravenous ciprofloxacin . AJM. Nov. 30 ; 87 (suppl 5 A). 92s – 97s)
4-Caekenberge, D.V. Stefanr Pattyn (1984). In vitro activity of ciprofloxacin compared with those new fluorinated piprazinyi supstituted quinoline derevatives.
Antimicrobial agent chemotherapy 25(3) 518-521.
5- Frost, R.W; Lettieri ;. J.T; Krol G; Shambien E.C and Laiseter K.C (1989) . The effect of cirohosis on the steady-state pharmacokinetics of oral ciprofloxacin .
Pharmacol. Ther. 45: 608 – 616.
6-Gudiol F ; Carmen Cabellos ; Roman Pallares; Josefina L; Javier A (1989). Intravenous ciprofloxacin therapy severe infections AJM.
Nov. 30 87 (suppl. 5 A): 2218 -227S.
7- Halkin G. (1988). Adverse effects of the fluoroquinolo - nes . Rview of infectious disease. 10 ( suppl./1 ): 5258 5261.
8- Harper A. Harlod (1971). Review of physiological chemistry (15 th.) edition. Lange . Medical publication . San Francisco. Japan.
9-Neer T.M. (1988). Clinical pharmacological features of fluoroquinolone antimicrobial drugs .JAVMA. 193 (5): 577 -579.
10- Richards D.M; Mouk J.P; Price . A; Field . B; Todd P.A. and ward (1988). Ciprofloxacin : a review of its antibacterial activity pharmacokinetic properties and
therapeutics use . Drugs . 53, 373 – 447.
11- Schacht P; hullman R. (1989) Safety of oral ciprofloxacin . A.JM. 87 (suppl. 5A ): 989 -102s.
12- Schalm D.W; Jain N.C. and Carroll E.J. (1980) Veterinary hematology (4'h.) edition . P(514). Lea Febbiger , Philadelphia
13- Shah, P.M; Rotraud M (1990) · Safety profile of quinolones . Eur. Uro ; 17(suppl / 1): 46 – 51 (13ref).
14- Villenenve, J.P; Davies C and Cote J. (1995) suspected ciprofloxacin induced hepatotxicity. Ann.
Pharmacotherapy , 29: 257 – 259.
15- Wolfson, J.S. and Hooper D.C. (1985) . The fluoro quinolones structure , mechanism of action resistance and spectra of activity invitro. Antimicrob .Agents and Chemother.
28: 581 - 586.